Prothrombin Gene G20210A Variant in Angiographically Documented Patients with Coronary Artery Stenosis

Leyla Pourgholi1, Hamidreza Goodarzynejad2, Shayan Ziaee1

  • 1Department of Molecular Pathology, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.

Insights

The prothrombin G20210A variant was not found to be a significant risk factor for coronary artery disease (CAD) or its severity in this study. Further research is needed to clarify the role of this genetic variant in cardiovascular health.

Area of Science:

  • Cardiovascular Genetics
  • Thrombosis Research

Background:

  • Inconclusive evidence links the prothrombin G20210A variant to coronary artery disease (CAD) risk.
  • The role of this genetic variant in CAD development and progression requires further investigation.

Purpose of the Study:

  • To investigate the association between the prothrombin G20210A variant and the presence and severity of CAD.
  • To determine if the G20210A variant influences CAD risk or its clinical manifestation.

Main Methods:

  • 1460 patients undergoing elective coronary angiography were enrolled.
  • Coronary angiography assessed CAD presence and severity using Gensini and vessel scores.
  • Prothrombin G20210A genotypes were determined using PCR-RFLP.

Main Results:

  • No statistically significant difference in Gensini scores between wild-type (GG) and mutant (AA+GA) genotypes (P=0.440).
  • No significant linear trend observed for the number of diseased vessels (vessel score) in relation to genotype (P=0.765).

Conclusions:

  • The study did not confirm the prothrombin G20210A variant as a significant determinant of CAD risk.
  • The G20210A variant does not appear to influence the severity of coronary artery disease in this patient cohort.

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
17.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
214
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
945
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
278